BeyondSpring, Inc. · NASDAQ:BYSI

BeyondSpring — Investor Presentation (April 2023)

43 slides from BeyondSpring's investor presentation, April 2023

  1. Slide 1: April 2023 | NASDAQ: BYSI

    April 2023 | NASDAQ: BYSI

  2. Slide 2: Disclaimer

    Disclaimer This presentation has been prepared for informational purposes only. No money or other consideration is being solicited, and if sent in response, will not be accepted. This presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shal

  3. Slide 3: Highlights

    Highlights SEED: Novel TPD Subsidiary SEED: Target Protein Degradation (TPD) Company with Eli Platform& Pipeline Lilly R&D Collaboration Plinabulin: Phase Positive Phase 3 data in 2 indications with Lead Asset - Plinabulin 3 Clinical Asset Global Regulatory Plinabulin: Target US, China, and EU Regul

  4. Slide 4: Pipeline

    Pipeline Indication/Targ Program Preclinical Phase 1 Phase 2 Phase 3 Registration Trial Name / Collaborator et NSCLC Plinabulin + Docetaxel DUBLIN-3 (2nd/3rd line) Late stage Plinabulin; PROTECTIVE-1 CIN Prevention Plinabulin + & PROTECTIVE-2 Pegfilgrastim SCLC Plinabulin + PD-1 + (2nd/3rd line) CTL

  5. Slide 5: SEED Overview

    SEED Overview SEED is a Molecular Glue company overcoming the critical hurdle for E3 selection to target any Disease- Causing Protein Since Lilly partnership in Nov. 2020, SEED has developed and applied its breakthrough target-centric MG discovery platform to internal and partnered projects Develop

  6. Slide 6: Plinabulin Franchise

    Plinabulin Franchise Clinical Confirmation Expand Transform Promising early clinical efficacy data Positive topline Phase 3 OS data Confirmed in 6 clinical studies & NDA Review in China CIN NSCLC Multiple Cancers (I/O Combo) 6

  7. Slide 7: SEED Therapeutics: TPD Company

    SEED Therapeutics: TPD Company 7

  8. Slide 8: Impossible Task of Identifying the Right E3 Ligase by HTS

    Impossible Task of Identifying the Right E3 Ligase by HTS Which of the thousands of disease- causing protein targets should be Which protein-protein selected for molecular glue discovery interaction (PPI) assay and development? platform should be developed for HTS? Which chemical library should be u

  9. Slide 9: SEED's Unique Platform to Identify Novel E3 for Protein of Interest

    SEED’s Unique Platform to Identify Novel E3 for Protein of Interest (POI) • Selection of E3 based on structure complementarity with POI • Selection of E3 in cell-based LumID platform • Biochemical assays to confirm baseline interaction of selected E3 and POI 9

  10. Slide 10: World-leading Experts Founding Team with Nobel Prize Winner

    World-leading Experts Founding Team with Nobel Prize Winner Ideas and Support from World-Leading Experts Translate at SEED to Future Medicine Avram Hershko Ning Zheng, Michele James Tonra, Lan Huang, MD, PhD PhD Pagano, MD PhD PhD Pioneer in the Pioneer in World leader in Expert in bench- Ubiquitin

  11. Slide 11: R&D Expertise and Infrastructure

    R&D Expertise and Infrastructure Discovery Labs, City of Science, King of Prussia, PA • Occupied 10,000 ft2 in June 2022 • 7000 ft2 lab space SEED: Combined R&D Team Experience • >100 years combined in small molecule hit-to-lead and lead optimization work • >60 years Medicinal Chemistry and SBDD wor

  12. Slide 12: Partnership with Eli Lilly Provides Early Validation and Funding

    Partnership with Eli Lilly Provides Early Validation and Funding • On November 13, 2020, SEED Therapeutics announced it has entered into a research collaboration and license agreement with Eli Lilly on targeted protein degradation. • Under the terms of the agreement, SEED Therapeutics will • Receive

  13. Slide 13: Success with Eli Lilly Project 1: High Value Disease-Causing Target

    Success with Eli Lilly Project 1: High Value Disease-Causing Target 1. Lilly 2. SEED 3. SEED / Lilly Target rationale Potential E3 Ligase Workflow Development Identification Joint Steering Committee Approval Disease-Causing Target Protein (nM) 4. SEED 5. SEED Protein Synthesis HTS TR-FRET Assay Deve

  14. Slide 14: Molecular Glue Nonclinical R&D Flow to Success

    Molecular Glue Nonclinical R&D Flow to Success Structure-based drug design For Partners, SEED delivers Molecular (SBDD) from known chemical Glue Leads against Nominated Targets, Molecular Glue matter, combined with key with activity in cells and disease models. Disease-Causing Protein Target(s) scre

  15. Slide 15: SEED's Breakthrough and Exclusive Molecular Glue Discovery Advantage

    SEED’s Breakthrough and Exclusive Molecular Glue Discovery Advantage: Discovery and Use of Basal Interaction LumID: identify nearby E3 in a cell Novel E3 Discovery No Photocatalyst No Biotinylation Warhead IP/Western from KRAS No Light mutant CRC cell lysates Interaction with 250KDa Cereblon made 13

  16. Slide 16: SEED Drug R&D Pipeline in Various Important Disease Areas

    SEED Drug R&D Pipeline in Various Important Disease Areas E3:Target Native HTS: PPI Target Selection E3 Candidate ID Protein Synthesis Hit to Lead ID PPI Screen Molecular Glue ID Target Protein Initiative Cancer: Project X Cancer KRAS-G12D Cancer Target#3 Cancer Target#4 NeuroD Target#1 NeuroD Targe

  17. Slide 17: Project X: Lead ST-00937 is Active To Degrade Target Protein in Cell

    Project X: Lead ST-00937 is Active To Degrade Target Protein in Cell Potent Cancer Cell Killing Disease-Causing Protein Degradation 6h 24 h Target Protein Vinculin CTG: CellTiter-Glo® 17

  18. Slide 18: Project X: Lead ST-00937 Regresses Tumors Growing in Mice

    Project X: Lead ST-00937 Regresses Tumors Growing in Mice Human colorectal cancer xenograft in immunodeficient mice; Oral dose, twice daily Superb In Vivo Efficacy: Good Safety: Complete Tumor Regression No Weight Loss 1000 35 Tumor Volume(mm3) 800 Body Weight (g) 30 600 25 400 200 20 0 15 0 3 6 9 1

  19. Slide 19: TPD Growth Opportunities in TPD Biotechs

    TPD Growth Opportunities in TPD Biotechs PROTAC /Heterobifunctional Molecular Glue Non-UPS Degrader Molecular Glue or Technology & PROTAC Focused Clinical Stage Preclinical Stage Discovery 19

  20. Slide 20: Differentiation by TPD Strategies

    Differentiation by TPD Strategies Molecular Glue Covalent binder libraries E3:Target Protein • Lack of evidence of target Basal Interaction specificity • No consideration for Basal importance of Basal Cell-based HTS assays LumID • May not be MG selective Affinity Interaction • Difficult to screen at

  21. Slide 21: Plinabulin: First-in-class Agent for Multiple Cancer Indications

    Plinabulin: First-in-class Agent for Multiple Cancer Indications 21

  22. Slide 22: Plinabulin: First-in-class MOA and Novel Chemical Entity

    Plinabulin: First-in-class MOA and Novel Chemical Entity Plinabulin: First-in-Class, Selective Immunomodulating Microtubule-Binding Agent (SIMBA) - Plinabulin Induces Dendritic Cell Maturation (the most potent APC), a Key Step in Initiating Anti-Cancer Durable Response ❷ Plinabulin Stimulate maturat

  23. Slide 23: Plinabulin Overview

    Plinabulin Overview 1 Favorable Safety Profile 1. >700 patients have been treated with plinabulin 2. Ease of Use: 1 or 2 doses per cycle given by 30~60 minutes IV infusion 2 CIN Prevention Benefit 1. Single Agent Plinabulin 2. Combination Plinabulin + Pegfilgrastim 3 Dual Anti-Cancer Mechanism of Ac

  24. Slide 24: Chemotherapy-Induced Neutropenia (CIN) Prevention Indication

    Chemotherapy-Induced Neutropenia (CIN) Prevention Indication 24

  25. Slide 25: CIN Is an Unmet Medical Need in Week 1 After Chemotherapy

    CIN Is an Unmet Medical Need in Week 1 After Chemotherapy Despite widespread G-CSF use, CIN is #1 reason for FN, ER visits, hospitalization, sepsis, mortality, and chemotherapy dose reduction and disruption1 Short-term Long-term G-CSF is more effective in week 2 after chemo Chemotherapy’s anti-cance

  26. Slide 26: Met Primary Endpoint in PROTECTIVE-2 Phase 3 Study

    Met Primary Endpoint in PROTECTIVE-2 Phase 3 Study Design: Double blind, global study (19 centers); 4 cycles Plinabulin 40 mg + Pegfilgrastim 6 mg N=111 Breast Cancer, R TAC Therapy 1:1 Placebo + Pegfilgrastim 6 mg N=110 Results: Proportion of Patients with NO Grade 4 Neutropenia (or DSN= 0 Days) in

  27. Slide 27: The Combination with Superior Improvement in Clinically Meaningful Endpoints

    The Combination with Superior Improvement in Clinically Meaningful Endpoints Compared to Pegfilgrastim Alone Reduction of Incidence and Reduction of Profound Improvement of Severity of FN and Neutropenia (PN) Related Quality of Life Hospitalization Benefits Clinical Endpoints Profound Neutropenia En

  28. Slide 28: 2nd/3rd Line NSCLC Indication

    2nd/3rd Line NSCLC Indication 28

  29. Slide 29: Severe Unmet Medical Needs – 2nd/3rd Line NSCLC, EGFR Wild Type

    Anti- Cancer Severe Unmet Medical Needs – 2nd/3rd Line NSCLC, EGFR Wild Type • Large patient population with limited treatment options o EGFR wild type: ~85% western NSCLC and ~70% of Asian NSCLC patients o With immunotherapies moved to first line, Docetaxel-based therapies are the mainstay therapy

  30. Slide 30: Met Primary Endpoint of OS in DUBLIN-3 Phase 3 Trial

    Met Primary Endpoint of OS in DUBLIN-3 Phase 3 Trial Design: Single-Blinded (blinding for patients only), global study, around 60 sites Docetaxel + Plinabulin (DP) 2nd/3rd line R NSCLC, EGFR Wild Type 1:1 Docetaxel + Placebo (D) 50% 43.48% 45% 40.47% Results: 40% 35% • Significantly increased 31.11%

  31. Slide 31: Met Primary Objective in Overall Survival (OS)

    Anti- Cancer Met Primary Objective in Overall Survival (OS) HR = 0.82 31

  32. Slide 32: Significant Reduction in Grade 4 Neutropenia

    Significant Reduction in Grade 4 Neutropenia Cycle 1 Day 8 and All Cycles Day 8 Grade 4 neutropenia, Cycle 1 Day 8 Grade 4 neutropenia, All Cycles Day 8 50% 50% P<0.0001 P<0.0001 40% 40% Percentage of Patients Percentage of Patients 33.58% 30% 27.80% 30% 20% 20% 10% 10% 5.26% 5.13% 0% 0% Docetaxel +

  33. Slide 33: Significant Improvement in Quality of Life

    Anti- Significant Improvement in Quality of Life Cancer - Q-TWiST (Quality-Adjusted Time Without Symptoms of Disease and Toxicity) Plinabulin + Docetaxel Docetaxel alone Clinically Meaningful Improvement of >18% in Q-TWiST. 33

  34. Slide 34: Potential Benefit of Plinabulin + Docetaxel in NSCLC (2nd/3rd line)

    Anti- Potential Benefit of Plinabulin + Docetaxel in NSCLC (2nd/3rd line) Cancer With PD-1/PD-L1 moving to 1st line NSCLC, plinabulin + docetaxel could be the potential choice, with benefits vs. Docetaxel. • Significant survival benefit, with more pronounced survival benefit in non-squamous NSCLC po

  35. Slide 35: Immuno-Oncology Combinations

    Immuno-Oncology Combinations 35

  36. Slide 36: Plinabulin as Potential Cornerstone Add-on Therapy to Current I/O Regimens

    Plinabulin as Potential Cornerstone Add-on Therapy to Current I/O Regimens to Address Severe Unmet Medical Needs PD-1/PD-L1 Inhibitors Potential to greatly expand the - $30B global annual sales addressable market Current Severe Unmet Medical Needs Plinabulin Clinical Development 2/3rd Line: PD-1/PD-

  37. Slide 37: Promising Efficacy (Phase I) Plinabulin + PD-1 + CTLA-4 Inhibitors in SCLC

    I/O Promising Efficacy (Phase I) Plinabulin + PD-1 + CTLA-4 Inhibitors in 2nd/3rd line SCLC Efficacy Analysis (ASCO 2021 Presentation) Waterfall plot of best overall response in target lesions compared to baseline PD-1/PD-L1 PD-1/PD-L1 Efficacy resistant therapy naïve Analysis (n=7) (n= 6) Number of

  38. Slide 38: Regulatory Pathway & Commercial Plan

    Regulatory Pathway & Commercial Plan 38

  39. Slide 39: Regulatory Pathway

    Regulatory Pathway Near-Term Long-Term CIN: Resubmit NDA to NMPA in Seek regulatory clarity and China; additional approvals in the US and EU, and countries around the NSCLC: Submit for NDA approval world. in China. 39

  40. Slide 40: Hengrui is the Ideal Partner for Plinabulin in Greater China

    Hengrui is the Ideal Partner for Plinabulin in Greater China Exceptional synergy between plinabulin and Hengrui pipeline ➢ Hengrui is the leader in oncology product R&D and commercialization in China • Established in 1970; Listed on Shanghai Stock Exchange in 2000 (Shanghai stock exchange ticker: 60

  41. Slide 41: Commercial Potential in CIN Prevention Market in China

    Commercial Potential in CIN Prevention Market in China G-CSF product sales in China (¥100,000,000) Overview of marketed long-acting G-CSF products in China2 Cost per cycle Cost per cycle Medical Product Company Availability (Original) (Latest winning bid) Insurance +40% 803 Short-lasting G-CSF 津优力 2

  42. Slide 42: Summary

    Summary SEED: Novel TPD Subsidiary SEED: Target Protein Degradation (TPD) Company with Eli Platform& Pipeline Lilly R&D Collaboration Plinabulin: Phase Positive Phase 3 data in 2 indications with Lead Asset - Plinabulin 3 Clinical Asset Global Regulatory Plinabulin: Target US, China, and EU Regulato

  43. Slide 43: www.beyondspringpharma.com

    www.beyondspringpharma.com 43

BeyondSpring — Investor Presentation (April 2023) on 6ix